273 related articles for article (PubMed ID: 23748869)
21. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic accuracy and usefulness of the Genotype MTBDRplus assay in diagnosing multidrug-resistant tuberculosis in Cameroon? a cross-sectional study.
Abanda NN; Djieugoué JY; Lim E; Pefura-Yone EW; Mbacham WF; Vernet G; Penlap VM; Eyangoh SI; Taylor DW; Leke RGF
BMC Infect Dis; 2017 May; 17(1):379. PubMed ID: 28569148
[TBL] [Abstract][Full Text] [Related]
23. Pulmonary resection in the treatment of multidrug-resistant tuberculosis: A case series.
Wang L; Xia F; Li F; Qian X; Zhu Y; Chen H; Bian A; Wang J; Zhang M; Li H; Han J; Jiang N; Xu N; Song Y
Medicine (Baltimore); 2017 Dec; 96(50):e9109. PubMed ID: 29390307
[TBL] [Abstract][Full Text] [Related]
24. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens.
Yew WW; Chan CK; Chau CH; Tam CM; Leung CC; Wong PC; Lee J
Chest; 2000 Mar; 117(3):744-51. PubMed ID: 10713001
[TBL] [Abstract][Full Text] [Related]
25. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
26. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
[TBL] [Abstract][Full Text] [Related]
27. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.
Chang KC; Leung CC; Yew WW; Leung EC; Leung WM; Tam CM; Zhang Y
Antimicrob Agents Chemother; 2012 Nov; 56(11):5465-75. PubMed ID: 22869570
[TBL] [Abstract][Full Text] [Related]
28. Performance of culture and drug susceptibility testing in pulmonary tuberculosis patients in northern China.
Qi W; Harries AD; Hinderaker SG
Int J Tuberc Lung Dis; 2011 Jan; 15(1):137-9. PubMed ID: 21276311
[TBL] [Abstract][Full Text] [Related]
29. Outcomes following surgery for complicated tuberculosis: analysis of 108 patients.
Bagheri R; Haghi SZ; Rajabi MT; Motamedshariati M; Sheibani S
Thorac Cardiovasc Surg; 2013 Mar; 61(2):154-8. PubMed ID: 22383153
[TBL] [Abstract][Full Text] [Related]
30. Predictor of multidrug resistant tuberculosis in southwestern part of Ethiopia: a case control study.
Gobena D; Ameya G; Haile K; Abreha G; Worku Y; Debela T
Ann Clin Microbiol Antimicrob; 2018 Jul; 17(1):30. PubMed ID: 29970076
[TBL] [Abstract][Full Text] [Related]
31. Risk factor analysis of postoperative complications after adjunctive pulmonary resection in patients with multidrug-resistant tuberculosis: A multi-institutional study.
Huang WL; Chien ST; Yu MC; Chang BS; Yen YT; Wu MH; Tseng YL
J Microbiol Immunol Infect; 2023 Oct; 56(5):1064-1072. PubMed ID: 37586914
[TBL] [Abstract][Full Text] [Related]
32. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors for surgical resection in patients with multidrug-resistant tuberculosis.
Kim HJ; Kang CH; Kim YT; Sung SW; Kim JH; Lee SM; Yoo CG; Lee CT; Kim YW; Han SK; Shim YS; Yim JJ
Eur Respir J; 2006 Sep; 28(3):576-80. PubMed ID: 16707517
[TBL] [Abstract][Full Text] [Related]
34. Factors contributing to the high prevalence of multidrug-resistant tuberculosis among previously treated patients: a case-control study from China.
Wang K; Chen S; Wang X; Zhong J; Wang X; Huai P; Wu L; Wang L; Jiang S; Li J; Peng Y; Yao H; Ma W
Microb Drug Resist; 2014 Aug; 20(4):294-300. PubMed ID: 24328894
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the socio-demographic and clinical features of pulmonary TB patients infected with sub-lineages within the W-Beijing and non-Beijing Mycobacterium tuberculosis.
Hu Y; Mathema B; Zhao Q; Zheng X; Li D; Jiang W; Wang W; Xu B
Tuberculosis (Edinb); 2016 Mar; 97():18-25. PubMed ID: 26980491
[TBL] [Abstract][Full Text] [Related]
36. Cross-sectional Whole-genome Sequencing and Epidemiological Study of Multidrug-resistant Mycobacterium tuberculosis in China.
Huang H; Ding N; Yang T; Li C; Jia X; Wang G; Zhong J; Zhang J; Jiang G; Wang S; Zong Z; Jing W; Zhao Y; Xu S; Chen F
Clin Infect Dis; 2019 Jul; 69(3):405-413. PubMed ID: 30321294
[TBL] [Abstract][Full Text] [Related]
37. Multidrug-resistant Mycobacterium tuberculosis: a report of cosmopolitan microbial migration and an analysis of best management practices.
Joean O; Thiele T; Schütz K; Schwerk N; Sedlacek L; Kalsdorf B; Baumann U; Stoll M
BMC Infect Dis; 2020 Sep; 20(1):678. PubMed ID: 32942990
[TBL] [Abstract][Full Text] [Related]
38. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China.
Tang S; Yao L; Hao X; Liu Y; Zeng L; Liu G; Li M; Li F; Wu M; Zhu Y; Sun H; Gu J; Wang X; Zhang Z
Clin Infect Dis; 2015 May; 60(9):1361-7. PubMed ID: 25605283
[TBL] [Abstract][Full Text] [Related]
39. Clinical evolution of a group of patients with multidrug-resistant TB treated at a referral center in the city of Rio de Janeiro, Brazil.
Siqueira HR; Freitas FA; Oliveira DN; Barreto AM; Dalcolmo MP; Albano RM
J Bras Pneumol; 2009 Jan; 35(1):54-62. PubMed ID: 19219331
[TBL] [Abstract][Full Text] [Related]
40. Chinese herbal medicine as adjuvant treatment to chemotherapy for multidrug-resistant tuberculosis (MDR-TB): A systematic review of randomised clinical trials.
Wang M; Guan X; Chi Y; Robinson N; Liu JP
Tuberculosis (Edinb); 2015 Jul; 95(4):364-72. PubMed ID: 25861717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
